Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-05-02
2011-10-18
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C536S024100, C514S04400A, C435S006120, C435S325000, C435S375000
Reexamination Certificate
active
08039609
ABSTRACT:
Aptamers against the glycosylated form of MUC1 are described, along with their use in treatment and diagnosis of conditions associated with elevated production of MUC1.
REFERENCES:
patent: 2006/0292643 (2006-12-01), Goletz et al.
patent: WO-03/003985 (2003-01-01), None
patent: WO-2004/014954 (2004-02-01), None
patent: WO-2004/022590 (2004-03-01), None
patent: WO-2004/065423 (2004-08-01), None
patent: WO-2004/081574 (2004-09-01), None
patent: WO-2005/019429 (2005-03-01), None
patent: WO-2005/111238 (2005-11-01), None
“Great Britain Application Serial No. GB0608778.7, Search Report dated Aug. 21, 2006”, 1 pg.
“International Application Serial No. PCT/GB2007/050234, International Search Report mailed Jan. 29, 2008”, 7 pgs.
“International Application Serial No. PCT/GB2007/050234, Written Opinion mailed Jan. 29, 2008”, 10 pgs.
Bäckström, M., et al., “Recombinant MUC1 mucin with a breast cancer-like 0-glycosylation produced in large amounts in Chinese-hamster ovary cells”,Biochemical Journal, 376(3), (Dec. 2003), 677-686.
Brokx, R. D, et al., “Nuclear Magnetic Resonance-Based Dissection of a Glycosyltransferase Specificity for the Mucin MUC1 Tandem Repeat”,Biochemistry, 42(47), (Dec. 2003), 13817-13825.
Fereira, C., et al., “DNA aptamers that recognize the MUC1 tumor marker (Poster No. 49)”,European Journal of Cancer.Supplement, vol. 2(8), (Sep. 2004), p. 19.
Mcdermott, K. M., et al., “Overexpression of MUCI Reconfigures the Binding Properties of Tumor Cells”,Int. J. Cancer, 94, (2001), 783-791.
Missailidis, S, et al., “Selection of aptamers with high affinity and high specificity against C595, an anti MUC1 IgG3 monoclonal antibody, for antibody targeting”,Journal Of Immunological Methods, 296(1-2), (Jan. 2005), 45-62.
Mueller, S., et al., “Recombinant MUC1 Probe Authentically Reflects Cell-Specific0-Glycosylation Profiles of Endogenous Breast Cancer Mucin. High Density and Prevalent Core 2-Based Glycosylation”,Journal of Biological Chemistry, 277(29), (Jul. 2002), 26103-26112.
Olson, F. J, et al., “A MUC1 tandem repeat reporter protein produced in CHO-K1 cells has sialylated Core 10-glycans and becomes more densely glycosylated if coexpressed with polypeptide-GaINAc-T4 transferase”,Glycobiology, 15(2), (Feb. 2005), 177-191.
Rughetti, A., et al., “Regulated expression of MUC1 epithelial antigen in erythropoiesis”,British Journal of Haematology, 120, (2003), 344-352.
Tuerk, C., et al., “Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase”,Science, 249(3), (Aug. 1990), 505-510.
Ferreira Catia Sofia Matos
Gariepy Jean
Missailidis Sotiris
Chong Kimberly
Schwegman Lundberg & Woessner, P.A.
The Open University
The University Health Network
LandOfFree
Aptamers directed to MUC1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aptamers directed to MUC1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aptamers directed to MUC1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293197